This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Gilead (GILD) HIV Sales Offset HCV Sales Decline in Q3?
by Zacks Equity Research
Gilead Sciences (GILD) is scheduled to report third-quarter results on Oct 25. We expect investors to focus on the strong HIV franchise and other pipeline updates.
Gilead Inks Gene Editing Collaboration Deal for HBV Infection
by Zacks Equity Research
Gilead (GILD) enters into a strategic collaboration with Precision BioSciences for developing therapies aimed at eliminating hepatitis B virus by using the latter's gene editing platform ARCUS.
Gilead's Rheumatoid Arthritis Drug Successful in Phase III
by Zacks Equity Research
Gilead (GILD) and partner Galapagos' rheumatoid arthritis candidate meets all primary and key secondary endpoints in first phase III study.
Vertex Completes Enrollment in Triple Combination Studies
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) completes enrollment in two phase III studies evaluating VX-659 triple combination regimen in CF patients. Data is expected in the fourth quarter of 2018.
Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint
by Zacks Equity Research
Gilead's (GILD) ankylosing spondylitis candidate, filgotinib meets primary endpoint in phase II study.
Vertex Inks Reimbursement Agreement for Orkambi in Australia
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) finalizes a reimbursement agreement with Australian government, which will improve the access to the drug.
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
The FDA accepts Catalyst's (CPRX) NDA for its lead pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and an action date of Nov 28, 2018 is set for the same.
Arena Pharmaceuticals (ARNA) Q2 Loss Wider Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) misses second-quarter earnings estimates. Its three key pipeline candidates, ralinepag, etrasimod and Olorinab/APD371, remain in focus.
Can the Rally in Galapagos (GLPG) Shares Continue?
by Zacks Equity Research
Galapagos NV (GLPG) has been on the move lately as the stock has risen by 23.4% in the past four weeks, and it is currently trading well above its 20-Day SMA
Galapagos (GLPG): Moving Average Crossover Alert
by Zacks Equity Research
Galapagos NV (GLPG) is looking like an interesting pick from a technical perspective
Vertex's Shares Rally as a Rival's CF Candidate Disappoints
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.
Gilead & Galapagos Announce Positive Data on Filgotinib
by Zacks Equity Research
Gilead (GILD) and partner Galapagaos (GLPG) announces positive data on filgotinib for the treatment of psoriatic arthritis in adults and ulcerative colitis.
New Strong Sell Stocks for February 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Lilly's Taltz Positive in Phase III Label Expansion Study
by Zacks Equity Research
Lilly's (LLY) psoriasis drug, Taltz, meets all endpoints in a phase III study evaluating it in patients with ankylosing spondylitis.
New Strong Sell Stocks for February 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for February 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Galapagos Reports Topline Data From Osteoarthritis Study
by Zacks Equity Research
Galapagos' (GLPG) osteoarthritis candidate, GLPG1972, reduces level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in an early stage study.
Galapagos' CF Candidate Shows Potential in Phase II Study
by Zacks Equity Research
Galapagos' (GLPG) CFTR corrector candidate, GLPG2222, shows potential in a phase II study on CF patients.
Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises 2017 View
by Zacks Equity Research
Vertex Pharma (VRTX) third-quarter earnings increased from the year-ago period led by strong sales of CF drugs.
Is a Surprise Coming for Galapagos (GLPG) This Earnings Season?
by Zacks Equity Research
Galapagos (GLPG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Quanta Services (PWR) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Quanta Services' (PWR) second-quarter 2017 earnings results will likely benefit from thriving engineering and project management services, but concerns like regulatory delays remain.
GoPro (GPRO) to Report Q2 Earnings: A Beat in Store?
by Zacks Equity Research
GoPro's (GPRO) second-quarter 2017 results should benefit from strong market traction of HERO5 cameras and restructuring measures, but risks of declining revenues and stiff competition remain.
Match Group (MTCH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Match Group's (MTCH) second-quarter 2017 earnings results should benefit from steady market traction and brand visibility, but concerns like currency volatility remain.
Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated's (VRTX) Q2 results were encouraging, as it topped earnings and revenues expectations backed by higher sales of both its CF drugs.
Will Flowserve (FLS) Pull Off a Surprise in Q2 Earnings?
by Zacks Equity Research
We expect second-quarter results of Flowserve (FLS) to gain traction from its strong operation model, solid productivity and geographical diversity.